This is the content of the pop-over!
  
Exam Edge Dark Logo Exam Edge Dark Logo
Business
Healthcare
Education
World


Recent Searches
Try searching for



CNCC - Canadian Critical Care (CNCC) Practice Tests & Test Prep by Exam Edge - Free Test


Our free Canadian Critical Care Nursing Examination (CNCC) Practice Test was created by experienced educators who designed them to align with the official Canadian Nursing content guidelines. They were built to accurately mirror the real exam's structure, coverage of topics, difficulty, and types of questions.

Upon completing your free practice test, it will be instantly reviewed to give you an idea of your score and potential performance on the actual test. Carefully study your feedback to each question to assess whether your responses were correct or incorrect. This is an effective way to highlight your strengths and weaknesses across different content areas, guiding you on where to concentrate your study efforts for improvement on future tests. Our detailed explanations will provide the information you need to enhance your understanding of the exam content and help you build your knowledge base leading you to better test results.

Login or Create an Account to take a free test

After you have completed your free test you will receive a special promo code that will save your between 10-15% on any additional practice tests!


** Sample images, content may not apply to your exam **

Additional test information
Back To General Exam Info

Canadian Critical Care Nursing Examination - Free Test Sample Questions

Tegison is the trade name for what drug?

Correct Answer:
etretinate


tegison is the trade name for the drug etretinate. etretinate is a medication that was primarily used for the treatment of severe psoriasis. it belongs to a class of drugs known as retinoids, which are synthetic derivatives of vitamin a. these drugs work by modulating the growth and differentiation of cells, which is particularly useful in conditions like psoriasis where skin cell production is significantly increased.

etretinate has been largely phased out in many countries due to its long half-life and the associated risks of prolonged toxicity. it has been replaced by acitretin, a metabolite of etretinate, which has a shorter half-life and is therefore considered safer for patient use. however, like etretinate, acitretin is also known for its teratogenic effects, meaning it can cause birth defects and is not recommended for use in pregnant women or women who plan to become pregnant.

while tegison (etretinate) was effective in treating severe cases of psoriasis, its use required careful management due to its side effects and potential for causing long-term health issues. regular monitoring and adherence to safety guidelines were essential for patients taking this medication. the availability of newer treatments with improved safety profiles has led to a decline in the use of etretinate over the years.